99.25

6.14% -6.49

After Hours: 98.42 -0.83 -0.84%

Rhythm Pharmaceuticals Inc (RYTM)

Overview News Price History Option Chain Financials Discussions Forecast

Rhythm Pharmaceuticals Inc stock is traded at $99.25, with a volume of 447.07K. It is down -6.14% in the last 24 hours and down -10.61% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Previous Close:

$105.74

Open:

$105.74

24h Volume:

447.07K

Relative Volume:

0.58

Market Cap:

$6.81B

Revenue:

$217.17M

Net Income/Loss:

$-202.68M

P/E Ratio:

-43.10

EPS:

-2.3028

Net Cash Flow:

$-156.63M

1W Performance:

-2.79%

1M Performance:

-10.61%

6M Performance:

-3.19%

1Y Performance:

+16.45%

1-Day Range:

$98.44

$106.87

1-Week Range:

$98.44

$110.99

52-Week Range:

$74.50

$122.20

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

857-264-4280

Address

222 BERKELEY STREET, BOSTON, MA

Employee

414

Twitter

@rhythmpharma

Next Earnings Date

2026-08-04

Latest SEC Filings

RYTM's Discussions on Twitter

Compare RYTM vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RYTM Rhythm Pharmaceuticals Inc	99.25	7.28B	217.17M	-202.68M	-156.63M	-2.3028
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	RBC Capital Mkts	Outperform
Nov-25-25	Initiated	Citigroup	Buy
Nov-05-25	Downgrade	Oppenheimer	Outperform → Perform
Jul-10-25	Initiated	Goldman	Buy
Jul-07-25	Initiated	Leerink Partners	Outperform
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy
Mar-05-25	Resumed	Stifel	Buy
Jan-02-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Guggenheim	Buy
Sep-18-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	JMP Securities	Mkt Outperform
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

Jul 28, 2026